Compare PRK & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRK | ZLAB |
|---|---|---|
| Founded | 1908 | 2013 |
| Country | United States | China |
| Employees | 1694 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.6B |
| IPO Year | 1996 | 2017 |
| Metric | PRK | ZLAB |
|---|---|---|
| Price | $177.93 | $25.53 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $199.50 | $33.48 |
| AVG Volume (30 Days) | 76.2K | ★ 989.1K |
| Earning Date | 10-26-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.45% | N/A |
| EPS Growth | 19.21 | ★ 38.46 |
| EPS | ★ 8.77 | N/A |
| Revenue | ★ $664,421,000.00 | $460,156,000.00 |
| Revenue This Year | $24.03 | N/A |
| Revenue Next Year | $3.17 | $26.74 |
| P/E Ratio | $32.40 | ★ N/A |
| Revenue Growth | 2.92 | ★ 15.33 |
| 52 Week Low | $149.06 | $15.96 |
| 52 Week High | $215.00 | $27.50 |
| Indicator | PRK | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 46.77 | 58.32 |
| Support Level | $168.61 | $24.24 |
| Resistance Level | $186.55 | $26.64 |
| Average True Range (ATR) | 5.49 | 1.25 |
| MACD | 0.22 | 0.14 |
| Stochastic Oscillator | 47.27 | 88.19 |
Park National Corp is a diversified financial services company based in Newark, Ohio, consisting of 11 community banking divisions with more than 100 offices in Ohio and Kentucky. The company provides the following principal services: the acceptance of deposits for demand, savings and time accounts; commercial, industrial, consumer and real estate lending, including installment loans, credit cards (which are largely offered through a third party), home equity lines of credit and commercial leasing; trust and wealth management services; cash management; safe deposit operations; electronic funds transfers; and a variety of additional banking-related services.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.